Trial Profile
A retrospective, observational study comparing efficacy of rifaximin dosing (400 mg thrice daily) compared to newer dosing (550 mg twice daily) in patients with recurrent hepatic encephalopathy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2017
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary) ; Lactulose; Metronidazole
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- 16 Feb 2017 New trial record
- 08 Feb 2017 Results published in the Journal of Gastroenterology and Hepatology